Юлия Александровна Татищева
Юлия Александровна Татищева has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- O. E. Lavrinovich
N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
5 shared publications - Андрей Петрович Карицкий
N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
5 shared publications - Alla S. Kalugina
Academician I.P. Pavlov First Saint Petersburg State Medical University
3 shared publications - Svetlana A. Kulyova
N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia; Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia
3 shared publications - Igor Viktorovitch Berlev
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
2 shared publications - M. G. Yakovleva
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
2 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by ECO-Vector LLC (Publications) in Journal of obstetrics and women's diseases
- Vol. 75 (4) , 56-65
The effect of spermatogenesis stimulation on embryological outcomes in assisted reproductive technology programs for patients with pathospermia: a prospective cohort study
BACKGROUND: Despite the widespread use of assisted reproductive technology (ART) treatments, the impact of the male factor on embryo quality remains insufficiently understood. Data regarding the effect of preconception stimulation of spermatogenesis on embryological outcomes in patients with pathospermia are limited and contradictory, which underscores the relevance of the present study. AIM: The aim of this study was to evaluate the effect of preconception care in men with pathospermia on spermatogenesis parameters and embryological outcomes in ART programs. METHODS: This prospective comparative study included 92 men with pathospermia undergoing ART treatment. The intervention group (n = 44) received a course of spermatogenesis stimulation therapy, whereas the control group (n = 48) underwent ART without prior preparation. The study groups were comparable in terms of male and female age, number of mature oocytes, and baseline semen characteristics. We assessed changes in spermatogenesis parameters and embryological outcomes, including the normal fertilization rate, number of day-5 embryos, total number of embryos obtained, and number of high-quality embryos. RESULTS: In the intervention group, sperm concentration, progressive motility, and normal morphology improved significantly following the stimulation therapy. However, we observed no effect of spermatogenesis stimulation on the fertilization rate (odds ratio 1.197; 95% confidence interval 0.860–1.665). In addition, the intervention group demonstrated higher numbers of day-5 embryos (p = 0.031), total embryos obtained (p = 0.041), and high-quality embryos (p = 0.045). The odds of obtaining a high-quality embryo were nearly twofold higher in patients who underwent spermatogenesis stimulation (odds ratio 1.88; 95% confidence interval 1.053–3.357). CONCLUSION: Male preconception care improves semen parameters and enhances embryo quality but does not affect fertilization rates in ART cycles. The observed effect is likely associated with improved sperm DNA integrity, which is not reflected by conventional semen analysis parameters. These findings support the use of spermatogenesis stimulation to optimize embryological outcomes and improve ART effectiveness. Further research is required to evaluate the impact of this approach on clinical ART outcomes, including pregnancy and live birth rates.
- 31 August 2026
- Published by ECO-Vector LLC (Publications) in Journal of obstetrics and women's diseases
- Vol. 75 (4) , 56-65
Open AccessThe effect of spermatogenesis stimulation on embryological outcomes in assisted reproductive technology programs for patients with pathospermia: a prospective cohort study
BACKGROUND: Despite the widespread use of assisted reproductive technology (ART) treatments, the impact of the male factor on embryo quality remains insufficiently understood. Data regarding the effect of preconception stimulation of spermatogenesis on embryological outcomes in patients with pathospermia are limited and contradictory, which underscores the relevance of the present study. AIM: The aim of this study was to evaluate the effect of preconception care in men with pathospermia on spermatogenesis parameters and embryological outcomes in ART programs. METHODS: This prospective comparative study included 92 men with pathospermia undergoing ART treatment. The intervention group (n = 44) received a course of spermatogenesis stimulation therapy, whereas the control group (n = 48) underwent ART without prior preparation. The study groups were comparable in terms of male and female age, number of mature oocytes, and baseline semen characteristics. We assessed changes in spermatogenesis parameters and embryological outcomes, including the normal fertilization rate, number of day-5 embryos, total number of embryos obtained, and number of high-quality embryos. RESULTS: In the intervention group, sperm concentration, progressive motility, and normal morphology improved significantly following the stimulation therapy. However, we observed no effect of spermatogenesis stimulation on the fertilization rate (odds ratio 1.197; 95% confidence interval 0.860–1.665). In addition, the intervention group demonstrated higher numbers of day-5 embryos (p = 0.031), total embryos obtained (p = 0.041), and high-quality embryos (p = 0.045). The odds of obtaining a high-quality embryo were nearly twofold higher in patients who underwent spermatogenesis stimulation (odds ratio 1.88; 95% confidence interval 1.053–3.357). CONCLUSION: Male preconception care improves semen parameters and enhances embryo quality but does not affect fertilization rates in ART cycles. The observed effect is likely associated with improved sperm DNA integrity, which is not reflected by conventional semen analysis parameters. These findings support the use of spermatogenesis stimulation to optimize embryological outcomes and improve ART effectiveness. Further research is required to evaluate the impact of this approach on clinical ART outcomes, including pregnancy and live birth rates.
- Open Access
- 11 September 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (4)
Fertility Preservation in Pre-Pubertal and Pubertal Cancer Female Patients
Введение. Важным методом сохранения фертильности у девочек препубертатного и пубертатного возраста является криоконсервация ткани яичника. Она имеет ряд преимуществ: не требуется стимуляции овуляции и отсрочки в начале полихимиотерапии. В настоящее время техническое совершенствование методик, связанных с лапароскопическим забором, хранением и аутотрансплантацией коры яичников, привело к показателю частоты живорождения от 35 до 40 % у взрослых пациенток с онкологическими заболеваниями. До 2019 г. метод оставался экспериментальным, но благодаря данной манипуляции сегодня в мире рождено уже более 200 детей, что позволило рекомендовать ее как один из основных способов сохранения фертильности. Лапароскопический забор, криоконсервация методом медленной заморозки перед началом специализированного лечения и аутотрансплантация ткани (коркового слоя) яичника после выздоровления в настоящее время может являться золотым стандартом сохранения фертильности для девочек, не достигших полового созревания. Однако в России до настоящего времени не разработан алгоритм реализации методов, критерии отбора, маршрутизация, юридическое сопровождение детей и их родителей (опекунов), нет централизованного криобанка для хранения биологического материала. Материалы и методы. Протокол клинического исследования инициирован в ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России и одобрен локальным комитетом по этике № 18 от 21.09.2023. Настоящая работа представляет собой одноцентровое рандомизированное исследование по сохранению фертильности у девочек препубертатного и пубертатного возраста. Планируется проведение скрининга примерно 120 пациентов для рандомизации примерно 50 человек. Популяция исследования — девочки и девушки до 18 лет с онкологическими заболеваниями. Заключение. Существуют достаточно эффективные, но все еще экспериментальные, методы сохранения фертильности у детей. В случае высокой гонадотоксичности противоопухолевой терапии у девочек возможно рассмотреть заморозку ткани яичника до начала лечения, хранение ее с последующей реимплантацией для восстановления фертильности во взрослом возрасте. Минусом данной манипуляции является инвазивность и необходимость выполнять ее под наркозом; плюсом — процедуру можно выполнять уже с первого года жизни девочки. Через год после достижения пациенткой полового созревания альтернативным методом может выступать стимуляция овуляции с последующей пункцией фолликулов в яичниках для криоконсервации ооцитов. Метод является малоинвазивным. Изучение актуальности и эффективности методов является важнейшей задачей сохранения фертильности детей.
- 11 September 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (4)
Open AccessFertility Preservation in Pre-Pubertal and Pubertal Cancer Female Patients
Введение. Важным методом сохранения фертильности у девочек препубертатного и пубертатного возраста является криоконсервация ткани яичника. Она имеет ряд преимуществ: не требуется стимуляции овуляции и отсрочки в начале полихимиотерапии. В настоящее время техническое совершенствование методик, связанных с лапароскопическим забором, хранением и аутотрансплантацией коры яичников, привело к показателю частоты живорождения от 35 до 40 % у взрослых пациенток с онкологическими заболеваниями. До 2019 г. метод оставался экспериментальным, но благодаря данной манипуляции сегодня в мире рождено уже более 200 детей, что позволило рекомендовать ее как один из основных способов сохранения фертильности. Лапароскопический забор, криоконсервация методом медленной заморозки перед началом специализированного лечения и аутотрансплантация ткани (коркового слоя) яичника после выздоровления в настоящее время может являться золотым стандартом сохранения фертильности для девочек, не достигших полового созревания. Однако в России до настоящего времени не разработан алгоритм реализации методов, критерии отбора, маршрутизация, юридическое сопровождение детей и их родителей (опекунов), нет централизованного криобанка для хранения биологического материала. Материалы и методы. Протокол клинического исследования инициирован в ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России и одобрен локальным комитетом по этике № 18 от 21.09.2023. Настоящая работа представляет собой одноцентровое рандомизированное исследование по сохранению фертильности у девочек препубертатного и пубертатного возраста. Планируется проведение скрининга примерно 120 пациентов для рандомизации примерно 50 человек. Популяция исследования — девочки и девушки до 18 лет с онкологическими заболеваниями. Заключение. Существуют достаточно эффективные, но все еще экспериментальные, методы сохранения фертильности у детей. В случае высокой гонадотоксичности противоопухолевой терапии у девочек возможно рассмотреть заморозку ткани яичника до начала лечения, хранение ее с последующей реимплантацией для восстановления фертильности во взрослом возрасте. Минусом данной манипуляции является инвазивность и необходимость выполнять ее под наркозом; плюсом — процедуру можно выполнять уже с первого года жизни девочки. Через год после достижения пациенткой полового созревания альтернативным методом может выступать стимуляция овуляции с последующей пункцией фолликулов в яичниках для криоконсервации ооцитов. Метод является малоинвазивным. Изучение актуальности и эффективности методов является важнейшей задачей сохранения фертильности детей.
- Open Access
- 4 August 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (3) , 172-179
Successful pregnancy after fertility preservation using OTO-IVM method in ovarian cancer
Fertility preservation in women of reproductive age with ovarian cancer is still challenging. The ovarian-sparing surgery may increase the risk of recurrence. The direct involvement of the ovary in the tumor process significantly limits the ability to implement the most effective fertility preservation methods. For example, ovarian stimulation and ovarian cortex cryopreservation are absolutely contraindicated due to the risk of tumor cell contamination. In such cases, the only feasible fertility preservation method may be OTO-IVM (Ovarian Tissue Oocyte In Vitro Maturation), which involves retrieving immature oocytes from ovarian tissue removed during surgery and subsequent in vitro maturation.Clinical Case Description. We present a case of successful pregnancy achieved through comprehensive, multidisciplinary fertility preservation. A 30-year-old patient with a recurrent borderline ovarian tumor in her only remaining ovary underwent surgery with uterine preservation and removal of the affected ovary. From the tumor-involved ovary, 22 cumulus-oocyte complexes were obtained. Following OTO-IVM, 12 metaphase II oocytes were obtained and fertilized via intracytoplasmic sperm injection (ICSI) that resulted in 3 blastocyst-stage embryos, which were cryopreserved. Cyclic hormone replacement therapy was administered to the patient. Nine months later, one embryo was thawed and transferred into the uterine cavity. Currently, an ongoing 20-week pregnancy has been confirmed.Conclusion. The OTO-IVM method holds significant value as a fertility preservation technique for patients with ovarian cancer, making childbirth achievable. Further research is needed to refine the method, optimize protocols, and define clear indications and contraindications for its application.
- 4 August 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (3) , 172-179
Open AccessSuccessful pregnancy after fertility preservation using OTO-IVM method in ovarian cancer
Fertility preservation in women of reproductive age with ovarian cancer is still challenging. The ovarian-sparing surgery may increase the risk of recurrence. The direct involvement of the ovary in the tumor process significantly limits the ability to implement the most effective fertility preservation methods. For example, ovarian stimulation and ovarian cortex cryopreservation are absolutely contraindicated due to the risk of tumor cell contamination. In such cases, the only feasible fertility preservation method may be OTO-IVM (Ovarian Tissue Oocyte In Vitro Maturation), which involves retrieving immature oocytes from ovarian tissue removed during surgery and subsequent in vitro maturation.Clinical Case Description. We present a case of successful pregnancy achieved through comprehensive, multidisciplinary fertility preservation. A 30-year-old patient with a recurrent borderline ovarian tumor in her only remaining ovary underwent surgery with uterine preservation and removal of the affected ovary. From the tumor-involved ovary, 22 cumulus-oocyte complexes were obtained. Following OTO-IVM, 12 metaphase II oocytes were obtained and fertilized via intracytoplasmic sperm injection (ICSI) that resulted in 3 blastocyst-stage embryos, which were cryopreserved. Cyclic hormone replacement therapy was administered to the patient. Nine months later, one embryo was thawed and transferred into the uterine cavity. Currently, an ongoing 20-week pregnancy has been confirmed.Conclusion. The OTO-IVM method holds significant value as a fertility preservation technique for patients with ovarian cancer, making childbirth achievable. Further research is needed to refine the method, optimize protocols, and define clear indications and contraindications for its application.
- Open Access
- 22 January 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (6)
Prerequisites for the Creation of a Program to Preserve Fertility in Children with Cancer
Успехи, достигнутые в терапии злокачественных опухолей у детей, привели к определенным проблемам у излеченных пациентов во взрослой жизни. Это связано с отдаленными последствиями противоопухолевого лечения. Особенно актуальным стал вопрос гонадотоксичности и снижения фертильности. На сегодня сохранение фертильности и детская онкология — это два «мира», которые постепенно сближаются. Варианты сохранения фертильности в перипубертатном и постпубертатном периоде хорошо известны и включают криоконсервацию яйцеклеток, эмбрионов или спермы. Методы сохранения фертильности в препубертатном периоде пока рассматриваются как экспериментальные. Многочисленные поиски активных исследований направлены на разработку технологий, которые позволят созревать незрелым яйцеклеткам и сперматозоидам и использовать их для рождения потомства в будущем. Кроме того, процедуры сохранения фертильности с медицинской точки зрения все-таки считаются необязательными, и родителям пациента нередко необходимо принять решение еще об одном, порой инвазивном, вмешательстве или преодолеть определенные этические проблемы.
- 22 January 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (6)
Open AccessPrerequisites for the Creation of a Program to Preserve Fertility in Children with Cancer
Успехи, достигнутые в терапии злокачественных опухолей у детей, привели к определенным проблемам у излеченных пациентов во взрослой жизни. Это связано с отдаленными последствиями противоопухолевого лечения. Особенно актуальным стал вопрос гонадотоксичности и снижения фертильности. На сегодня сохранение фертильности и детская онкология — это два «мира», которые постепенно сближаются. Варианты сохранения фертильности в перипубертатном и постпубертатном периоде хорошо известны и включают криоконсервацию яйцеклеток, эмбрионов или спермы. Методы сохранения фертильности в препубертатном периоде пока рассматриваются как экспериментальные. Многочисленные поиски активных исследований направлены на разработку технологий, которые позволят созревать незрелым яйцеклеткам и сперматозоидам и использовать их для рождения потомства в будущем. Кроме того, процедуры сохранения фертильности с медицинской точки зрения все-таки считаются необязательными, и родителям пациента нередко необходимо принять решение еще об одном, порой инвазивном, вмешательстве или преодолеть определенные этические проблемы.
- Open Access
- 30 October 2024
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (3) , 60-65
Ethical and legal issues of preserving childhood oncofertility
Providing a better quality of life for the children with cancer after recovery proves to be one and important aspect of rehabilitation. Preserving the fertility of children, adolescents and young adults can improve the chances to lead a full, active life, and have biological children after oncological treatment. It is necessary to consider that the degree of reproductive potential impairment as well as recovery perspectives can be assessed solely after the gonadotoxic therapy completion. Whereas fertility preservation practice proves to be more effective before the oncological treatment. The complexity of discussing with young patients and their parents (custodian parents) the risk of decrease or loss of reproductive function, of fertility preservation methods, of necessity to agree to another possible invasive intervention raises quite a range of ethical and legal problems, which claim special attention on behalf of doctors and patients’ protection.
- 30 October 2024
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (3) , 60-65
Open AccessEthical and legal issues of preserving childhood oncofertility
Providing a better quality of life for the children with cancer after recovery proves to be one and important aspect of rehabilitation. Preserving the fertility of children, adolescents and young adults can improve the chances to lead a full, active life, and have biological children after oncological treatment. It is necessary to consider that the degree of reproductive potential impairment as well as recovery perspectives can be assessed solely after the gonadotoxic therapy completion. Whereas fertility preservation practice proves to be more effective before the oncological treatment. The complexity of discussing with young patients and their parents (custodian parents) the risk of decrease or loss of reproductive function, of fertility preservation methods, of necessity to agree to another possible invasive intervention raises quite a range of ethical and legal problems, which claim special attention on behalf of doctors and patients’ protection.
- Open Access
- 9 September 2024
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 23 (4) , 96-107
OTO-IVM is a method of fertility preservation for patients with ovarian tumors
Introduction. An increasing number of patients of reproductive age get cancer and are highly interested in preserving fertility. Survival rates for cancer patients are improving. Methods of reproductive technologies are being improved to preserve the ability to bear children. Rehabilitation aimed to ensure a satisfactory quality of life takes on a new meaning, and with the development of new technologies, the level of possible assistance also changes. Today, rehabilitation measures for cancer patients of reproductive age should undoubtedly include all possible ways to preserve and restore fertility. Aim: preservation of fertility in patients with ovarian tumors. Material and Methods. After ovariectomy, the ovaries were transported to the embryology laboratory, where oocyte-cumulus complexes were extracted and subsequently matured using the OTO-IVM (ovarian tissue oocyte in vitro maturation) method. The resulting mature oocytes (Metaphase II) were cryopreserved by vitrification or, if a partner was available, fertilized by ICSI (intracytoplasmic sperm injection), the embryos were cultured to the blastocyst stage and also cryopreserved by vitrification. Cryopreserved oocytes and embryos can be used by patients after cancer treatment in assisted reproductive technology programs. Results. A total of 218 OCCs were recovered, 29.8 % were degraded oocytes (n=65). The proportion of OCC suitable for ripening was 153 (70.2 %). After 36 or 48 hours, 65 oocytes matured in 13 patients, which amounted to 42.5 % of oocytes without signs of degradation. In 11 patients the OCC was removed from the tumor-affected ovary. 149 oocytes were obtained, of which 50 (33.6 %) were oocytes with signs of degradation. The remaining 99 (66.4 %) of OCCs had satisfactory quality; after maturation, the Metaphase II stage reached in 49 (49.5 %) of oocytes. As a result, biological material was cryopreserved in 13 of 15 patients: 5 embryos and 60 oocytes.
- 9 September 2024
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 23 (4) , 96-107
Open AccessOTO-IVM is a method of fertility preservation for patients with ovarian tumors
Introduction. An increasing number of patients of reproductive age get cancer and are highly interested in preserving fertility. Survival rates for cancer patients are improving. Methods of reproductive technologies are being improved to preserve the ability to bear children. Rehabilitation aimed to ensure a satisfactory quality of life takes on a new meaning, and with the development of new technologies, the level of possible assistance also changes. Today, rehabilitation measures for cancer patients of reproductive age should undoubtedly include all possible ways to preserve and restore fertility. Aim: preservation of fertility in patients with ovarian tumors. Material and Methods. After ovariectomy, the ovaries were transported to the embryology laboratory, where oocyte-cumulus complexes were extracted and subsequently matured using the OTO-IVM (ovarian tissue oocyte in vitro maturation) method. The resulting mature oocytes (Metaphase II) were cryopreserved by vitrification or, if a partner was available, fertilized by ICSI (intracytoplasmic sperm injection), the embryos were cultured to the blastocyst stage and also cryopreserved by vitrification. Cryopreserved oocytes and embryos can be used by patients after cancer treatment in assisted reproductive technology programs. Results. A total of 218 OCCs were recovered, 29.8 % were degraded oocytes (n=65). The proportion of OCC suitable for ripening was 153 (70.2 %). After 36 or 48 hours, 65 oocytes matured in 13 patients, which amounted to 42.5 % of oocytes without signs of degradation. In 11 patients the OCC was removed from the tumor-affected ovary. 149 oocytes were obtained, of which 50 (33.6 %) were oocytes with signs of degradation. The remaining 99 (66.4 %) of OCCs had satisfactory quality; after maturation, the Metaphase II stage reached in 49 (49.5 %) of oocytes. As a result, biological material was cryopreserved in 13 of 15 patients: 5 embryos and 60 oocytes.